RxDoctor Payments Data

Melissa Davis

Primary Care · Brookhaven, MSNPI 1609396076

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 51.0% of the total.

$556in general payments, 2019–2025

Across 31 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$284
  • SK Life Science, Inc.$100
  • Otsuka America Pharmaceutical, Inc.$42
  • Sumitomo Pharma America, Inc.$37
  • Teva Pharmaceuticals USA, Inc.$23
  • Averitas Pharma Inc.$17
  • plus $54 from 4 others

What the payments were for

  • Food & beverage$556100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$556 in reported general payments places this provider in the 55th percentile of 80 primary care providers in Mississippi.

See all primary care providers in Mississippi

Medicare billing

Part B allowed, 2024
$16,988
Medicare patients
52
Services billed
405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$29,649
Albuterol Sulfate HfaAlbuterol Sulfate21$448
Omeprazole27$288
Hydroxyzine Pamoate24$278
Ondansetron OdtOndansetron13$240
Gabapentin18$230
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav21$200
Losartan Potassium21$159
Atorvastatin Calcium25$143
Amlodipine Besylate19$112
Azithromycin22$106
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$95
Levothyroxine Sodium22$89
Pantoprazole Sodium12$88
Escitalopram Oxalate12$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$12$29,64920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 80 primary care providers in Mississippi.

Other primary care in Brookhaven

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →